Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ciro Gallo

Showing results (11-20 of 112) with videos related to

Pageof 12
Sort By:
Nature Clinical Practice. Oncology|March 8, 2006
Chemotherapy-induced neutropenia: a useful predictor of treatment efficacy?Massimo Di Maio, Cesare Gridelli, Ciro Gallo, et al.
The Lancet. Oncology|May 30, 2014
Carboplatin plus paclitaxel scheduling for advanced ovarian cancer - authors' replySandro Pignata, Massimo Di Maio, Ciro Gallo, et al.
Journal of Clinical Epidemiology|May 11, 2020
Hamilton scale and MADRS are interchangeable in meta-analyses but can disagree at trial levelLorenzo Guizzaro, David Dickinson Vaughan Morgan, Andrea Falco, et al.
European Journal of Gastroenterology & Hepatology|March 15, 2016
A prognostic index for patients within the intermediate stage of hepatocellular carcinomaGiovan Giuseppe Di Costanzo, Simona Signoriello, Raffaella Tortora, et al.
Contemporary Clinical Trials Communications|October 12, 2020
A phase 2, open label, multicenter, single arm study of tocilizumab on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19 trial): Statistical analysis planPaolo Chiodini, Laura Arenare, Maria Carmela Piccirillo, et al.
Clinical Lung Cancer|July 25, 2008
An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH trialCesare Gridelli, Charles Butts, Fortunato Ciardiello, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2013
Reply to V. Lorusso et alCesare Gridelli, Ciro Gallo, Charles A Butts, et al.
Journal of Oncology Practice|May 25, 2019
Assessing Financial Toxicity in Patients With Cancer: Moving Away From a One-Size-Fits-All ApproachFrancesco Perrone, Massimo Di Maio, Fabio Efficace, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 13, 2008
Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregressionFausta Catapano, Paolo Chiodini, Luca De Nicola, et al.
Italian Journal of Pediatrics|February 19, 2014
Epidemiological study on behavioural and emotional problems in developmental age: prevalence in a sample of Italian children, based on parent and teacher reportsAntonella Gritti, Carmela Bravaccio, Simona Signoriello, et al.
Pageof 12

Showing results (11-20 of 112) with videos related to

Sort By:
Pageof 12
Nature Clinical Practice. Oncology|March 8, 2006
Chemotherapy-induced neutropenia: a useful predictor of treatment efficacy?Massimo Di Maio, Cesare Gridelli, Ciro Gallo, et al.
The Lancet. Oncology|May 30, 2014
Carboplatin plus paclitaxel scheduling for advanced ovarian cancer - authors' replySandro Pignata, Massimo Di Maio, Ciro Gallo, et al.
Journal of Clinical Epidemiology|May 11, 2020
Hamilton scale and MADRS are interchangeable in meta-analyses but can disagree at trial levelLorenzo Guizzaro, David Dickinson Vaughan Morgan, Andrea Falco, et al.
European Journal of Gastroenterology & Hepatology|March 15, 2016
A prognostic index for patients within the intermediate stage of hepatocellular carcinomaGiovan Giuseppe Di Costanzo, Simona Signoriello, Raffaella Tortora, et al.
Contemporary Clinical Trials Communications|October 12, 2020
A phase 2, open label, multicenter, single arm study of tocilizumab on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19 trial): Statistical analysis planPaolo Chiodini, Laura Arenare, Maria Carmela Piccirillo, et al.
Clinical Lung Cancer|July 25, 2008
An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH trialCesare Gridelli, Charles Butts, Fortunato Ciardiello, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2013
Reply to V. Lorusso et alCesare Gridelli, Ciro Gallo, Charles A Butts, et al.
Journal of Oncology Practice|May 25, 2019
Assessing Financial Toxicity in Patients With Cancer: Moving Away From a One-Size-Fits-All ApproachFrancesco Perrone, Massimo Di Maio, Fabio Efficace, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 13, 2008
Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregressionFausta Catapano, Paolo Chiodini, Luca De Nicola, et al.
Italian Journal of Pediatrics|February 19, 2014
Epidemiological study on behavioural and emotional problems in developmental age: prevalence in a sample of Italian children, based on parent and teacher reportsAntonella Gritti, Carmela Bravaccio, Simona Signoriello, et al.
Pageof 12